Giuseppe Tarantini
Latest contributions
TAVI vs. surgery - Are the latest long-term data creating a dilemma for aortic stenosis patients?
21 May 2026 – From EuroPCR 2026
This session critically evaluates the latest long-term data comparing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR). It explores differing perspectives between surgeons and interventional cardiologists regarding valve durability and lifetime management, fostering a high-quality debate to achieve consensus within Heart Team discussions...
Active unloading with Impella heart pumps in elective and emergent patients
21 May 2026 – From EuroPCR 2026
This session presents the latest evidence on the use of microaxial Impella heart pumps in both elective high-risk and emergent cardiogenic shock patients. It highlights the importance of organised systems of care in improving survival outcomes and explores current data and expert consensus on mechanical circulatory...
Advancing TAVI practice
21 May 2026 – From EuroPCR 2026
Advancing TAVI practice is the focus of this session, addressing antiplatelet therapy choices, novel transcatheter treatments for pure aortic regurgitation, early hemodynamic valve deterioration as a prognostic marker, prosthesis-patient mismatch in redo-TAVI, pioneering valve-in-mechanical valve interventions, and comprehensive core-lab evaluation of implantation depth and clinical outcomes.
New evidence for coronary revascularisation
21 May 2026 – From EuroPCR 2026
This session highlights new evidence in coronary revascularisation, including the role of CT-derived virtual stenting for procedural optimization, left ventricular unloading during complex PCI, long-term outcomes of FFR-guided PCI versus medical therapy, Impella CP support in high-risk PCI, and comparative results of PCI versus CABG in...
Align for the future with structural heart innovations - LIVE case and major trial updates
19 May 2026 – From EuroPCR 2026
Stay abreast of structural heart innovations with expert discussions on best-in-class transcatheter aortic valve implantation (TAVI) practices, including imaging, sizing, and procedural strategies. This session with LIVE case introduces the novel Myval Octapro+ transcatheter heart valve (THV), its design philosophy, and potential clinical benefits, along with...
New evidence for pharmacology for coronary artery disease
19 May 2026 – From EuroPCR 2026
This session presents the latest evidence in pharmacological management of coronary artery disease, featuring pivotal trials such as VESALIUS-CV and TARGET FIRST. It covers topics including evolocumab efficacy post-stenting, early aspirin cessation strategies, aspirin-free protocols after complex PCI in ACS, and comparative outcomes of clopidogrel versus...
TAVI in bicuspid aortic valve disease
22 May 2025 – From EuroPCR 2025
Explore the unique challenges of TAVI in bicuspid aortic valve disease with a focus on long-term outcomes, residual gradients, prosthesis-patient mismatch, and anatomical subtype comparisons. This session draws on international registry data to inform clinical decision-making and optimize procedural strategies in this complex patient population.
Innovation to address unmet clinical needs in transcatheter valve therapies
22 May 2025 – From EuroPCR 2025
Discover innovations addressing unmet clinical needs in transcatheter valve therapies. This session shares case-based experiences including young aortic stenosis patients, mitral regurgitation with annular calcification, and severe tricuspid regurgitation with right ventricular dysfunction, alongside the latest advances in TAVI, TMVR, and tricuspid interventions.
The Landmark RCT - One-year results
21 May 2025 – From EuroPCR 2025
This session presents a detailed analysis of a landmark randomized controlled trial evaluating the Myval transcatheter aortic valve implantation (TAVI) system among other contemporary transcatheter valves. The discussion centers on one-year clinical outcomes, with a particular focus on women, patients with small aortic annuli, and those...
Cardiogenic shock and high-risk interventions with percutaneous mechanical circulatory support: new evidence and insights
20 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session offers a comprehensive update on cardiogenic shock and high-risk PCI, featuring expert analysis of the DanGer-SHOCK and ECLS-SHOCK trials, new insights one year after DanGer-SHOCK, and practical considerations for managing PCI in patients with severely reduced LVEF. Expect to gain a deeper...
